ezetimibe has been researched along with Infarction, Middle Cerebral Artery in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SP; Li, X; Matei, N; Mo, J; Pang, JW; Tang, JP; Wang, WN; Yan, M; Yu, J; Zhang, JH | 1 |
| Li, X; Matei, N; McBride, D; Tang, J; Yan, M; Yu, J; Zhang, JH | 1 |
2 other study(ies) available for ezetimibe and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Ezetimibe Attenuates Oxidative Stress and Neuroinflammation via the AMPK/Nrf2/TXNIP Pathway after MCAO in Rats.
Topics: AMP-Activated Protein Kinases; Animals; Cell Cycle Proteins; Disease Models, Animal; Ezetimibe; Infarction, Middle Cerebral Artery; Inflammation; Male; NF-E2-Related Factor 2; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2020 |
Ezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK dependent autophagy activation after MCAO in rats.
Topics: Administration, Intranasal; AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Apoptosis; Autophagy; Ezetimibe; Infarction, Middle Cerebral Artery; Injections, Intraventricular; Male; Membrane Transport Proteins; Neurons; Random Allocation; Rats; Rats, Sprague-Dawley | 2018 |